Jean-Pierre Latere, Philippe Parone, and the entire EsoBiotec team will continue their development of the EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform with an exciting new partner in AstraZeneca.  This is a tremendous milestone for patients as the combination of EsoBiotec and AZ will accelerate the development of their in vivo cell therapy technology which empowers the immune system to attack cancers while potentially increasing access to this transformative therapy for many more patients. This is also a great milestone for Wallonia, and Belgium as a whole, as this will further expand the critical biotechnology resources and infrastructure in the region.

We are excited to see what this impressive new team will achieve together, and we wholeheartedly congratulate JP and everyone at EsoBiotec for their tremendous hard work to get this far.

Link to press release: https://www.astrazeneca.com/media-centre/press-releases/2025/acquisition-of-esobiotec-completed.html